Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.

Her-Shyong ShiahNai-Jung ChiangChia-Chi LinChia-Jui YenHui-Jen TsaiShang-Yin WuWu-Chou SuKwang-Yu ChangChing-Chiung WangJang-Yang ChangLi-Tzong Chen

Published in: The oncologist (2020)

The MTD of SCB01A was 24 mg/m2 every 21 days; it is safe and tolerable in patients with solid tumors.

Keyphrases